Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Cash & Current Investments: 2020-2025

Historic Cash & Current Investments for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Sep 2025 value amounting to $191.1 million.

  • Arcutis Biotherapeutics' Cash & Current Investments fell 42.20% to $191.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $807.9 million, marking a year-over-year decrease of 40.97%. This contributed to the annual value of $228.0 million for FY2024, which is 16.15% down from last year.
  • Per Arcutis Biotherapeutics' latest filing, its Cash & Current Investments stood at $191.1 million for Q3 2025, which was up 0.13% from $190.8 million recorded in Q2 2025.
  • Arcutis Biotherapeutics' 5-year Cash & Current Investments high stood at $477.0 million for Q3 2022, and its period low was $190.8 million during Q2 2025.
  • In the last 3 years, Arcutis Biotherapeutics' Cash & Current Investments had a median value of $268.7 million in 2023 and averaged $273.2 million.
  • In the last 5 years, Arcutis Biotherapeutics' Cash & Current Investments soared by 93.59% in 2021 and then crashed by 52.38% in 2023.
  • Quarterly analysis of 5 years shows Arcutis Biotherapeutics' Cash & Current Investments stood at $387.1 million in 2021, then rose by 5.82% to $409.6 million in 2022, then crashed by 33.63% to $271.9 million in 2023, then fell by 16.15% to $228.0 million in 2024, then slumped by 42.20% to $191.1 million in 2025.
  • Its Cash & Current Investments was $191.1 million in Q3 2025, compared to $190.8 million in Q2 2025 and $198.1 million in Q1 2025.